Biotech
EDMONTON, ALBERTA: - Company posts best full-year financial performance in its history - - FY 2014 Revenues increased 36% vs. 2013 - - FY 2014 Net Profit increased 806% vs. 2013 -
...
SOUTH SAN FRANCISCO, CA: TH-4000 Overcomes Erlotinib Resistance in Heterozygous (Wild-Type/Mutant) EGFR Xenograft Lung Cancer Model; Preclinical Antitumor Activity Observed With Human-Equivalent Doses Lower Than the Maximum T ...
NORWOOD, MA: Award Supports Initiation of Phase 2 Clinical Trial With Resunab, a Novel Oral Anti-Inflammatory and Anti-Fibrotic Drug, in Individuals With Cystic Fibrosis; Study Expected to Begin This Quarter; Corb ...
PHILADELPHIA, PA: Data Support Potential of Tesevatinib in Treating Gliomas and Brain Metastases
...
SAN DIEGO, CA: Company Augments Efforts in Acceleration of Cancer Stem Cell Targeting Therapeutics
...
GEORGE TOWN, GRAND CAYMAN: Poster Presentations Provide Further Support for Role of VIBATIV(R) in Fight Against Antibiotic Resistance
...
NORWOOD, MA: Company to Ring The Nasdaq Stock Market Closing Bell on April 17, 2015
...
HALIFAX, NOVA SCOTIA: Presentation Highlights Increased Anti-Tumor Efficacy When Combining anti-PD-1 with DepoVaxT-based Vaccines
...
TOKYO, JAPAN: Antigen-Specific Immunotherapy to Potentially Prevent or Delay Diabetes in Preclinical Model
...
